InsidersTradesSigma
Follow the Charles River Laboratories International, INC. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Charles River Laboratories International, INC. has logged 341 public disclosures. Market capitalisation: €13.9bn. The latest transaction was reported on 20 August 2026 (Cession). Among the most active insiders: Knell Michael Gunnar. Every trade is accessible without an account.
341
Insider Decl.
n/a
Thresholds
€3m
7 ops.
Buy Volume
€34m
55 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Charles River Laboratories International, INC. Buy (bullish), based on 14 analysts. Average price target: US$281.00.
32Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,186 of 29,064 companies
28.2
score / 100
Value31
Quality25
FCF yld3.7%
Earn yld-1.0%
EV/EBITDA40.1x
ROE-7.5%
Gross mgn33%
Net mgn-3.6%
Debt/EBITDA6.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 August 2026
Declarations341 total
573 shares@ US$285.240.0012% mcap31.1% of flowCommon StockSEC:0001100682-26-000134:1
528 shares0Common StockSEC:0001100682-26-000138:0
2,039 shares@ US$194.120.0028% mcap4.7% of flowCommon StockSEC:0001100682-26-000136:0
573 shares@ US$164.300.0007% mcap17.9% of flowCommon StockSEC:0001100682-26-000134:0
2,039 shares@ US$294.120.0043% mcap7.1% of flowCommon StockSEC:0001100682-26-000136:1
2,039 shares@ US$294.120.0044% mcap8.1% of flowCommonSEC144:0001969223-26-000932
3,714 shares@ US$279.660.0076% mcap13.3% of flowCommon StockSEC:0001100682-26-000130:1
6,500 shares@ US$279.900.013% mcap15.2% of flowCommon StockSEC:0001100682-26-000132:1
3,714 shares@ US$179.660.0049% mcap8.5% of flowCommon StockSEC:0001100682-26-000130:0
6,500 shares@ US$179.660.0085% mcap9.8% of flowCommon StockSEC:0001100682-26-000132:0
3,714 shares@ US$279.660.0081% mcap17.0% of flowCommonSEC144:0001969223-26-000886
6,500 shares@ US$279.900.014% mcap20.3% of flowCommonSEC144:0001969223-26-000885
28,733 shares@ US$179.660.040% mcap7.6% of flowCommon StockSEC:0001100682-26-000126:0
257 shares0Common StockSEC:0001100682-26-000128:0
28,733 shares@ US$275.000.062% mcap11.7% of flowCommon StockSEC:0001100682-26-000126:1
28,733 shares@ US$275.000.062% mcap14.5% of flowCommonSEC144:0001969223-26-000874
4,179 shares@ US$179.660.0059% mcap12.1% of flowCommon StockSEC:0001100682-26-000122:0
4,179 shares@ US$259.160.0085% mcap17.4% of flowCommon StockSEC:0001100682-26-000122:1
1,274 shares@ US$259.070.0026% mcap7.2% of flowCommon StockSEC:0001100682-26-000124:0
810 shares@ US$261.450.0017% mcap4.6% of flowCommon StockSEC:0001100682-26-000124:2
213 shares@ US$262.370.0004% mcap1.2% of flowCommon StockSEC:0001100682-26-000124:3
482 shares@ US$265.170.0010% mcap2.8% of flowCommon StockSEC:0001100682-26-000124:5
404 shares@ US$179.660.0006% mcap1.6% of flowCommon StockSEC:0001100682-26-000124:6
1,205 shares@ US$194.120.0018% mcap5.1% of flowCommon StockSEC:0001100682-26-000124:7
404 shares@ US$258.530.0008% mcap2.3% of flowCommon StockSEC:0001100682-26-000124:9
25 of 341 declarations
关于 Charles River Laboratories International, INC.
Charles River Laboratories International, Inc. (股票代码: CRL) 是一家总部位于美国的上市公司，在美国纽约证券交易所 (NYSE) 上市。对于法国、比利时和瑞士的投资者而言，它代表着一项核心的生命科学服务和工具业务，位于制药价值链的早期阶段，因此受制药公司、生物技术公司、政府机构和学术机构的研发支出影响。该公司起源于 1947 年，当时它在波士顿查尔斯河畔成立了一个一人实验室。其总部后来迁至马萨诸塞州威尔明顿，至今仍在那里，该集团已发展成为一个全球战略合作伙伴，支持发现、早期开发和某些制造活动。([criver.com](https://www.criver.com/about-us/about-us-overview/our-story?utm_source=openai)) Charles River 的业务模式围绕几个互补的运营线构建。研究模型和服务提供实验动物模型，包括啮齿动物模型，以及支持基础和转化研究的相关服务。发现和安全评估提供临床前服务，如药理学、毒理学、病理学、安全评估和监管支持。该公司还拥有以制造和内部采购为导向的能力，支持生物制剂和开发工作流程；然而，在 2026 年，它宣布了一项最终协议，剥离其 CDMO 和细胞解决方案业务，表明其战略重点更明确地放在其更高价值的科学平台上。总的来说，该公司被定位为一体化的早期药物开发合作伙伴，而不是纯粹的 CRO 或独立的实验动物供应商。([ir.criver.com](https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-announces-third-quarter-2025-results?utm_source=openai)) 从竞争角度来看，Charles River 受益于深厚的科学专业知识、悠久的运营历史和广泛的国际足迹。该公司表示，它在 30 个国家运营着 130 多个设施，使其业务遍及北美、欧洲和亚洲，并能够为全球制药和生物技术客户提供本地化执行。这种规模，加上其在发现、临床前安全和研究模型方面的广度，支持了其在一个高度分散但对质量敏感的市场中的相关性。([criver.com](https://www.criver.com/about-us/about-us-overview/our-story?utm_source=openai)) 最近的发展对投资案例很重要。在 2026 年 2 月，Charles River 报告 2025 财年全年收入为 4.02 billion 美元，略低于上一年，同时强调了由重组和成本措施推动的非 GAAP 利润率改善。在 2026 年 5 月，该公司宣布其数字病理学平台持续发展势头，描述了一种支持 AI 的端到端工作流程，旨在缩短研究时间并提高病理学家的效率。管理层也一直在积极重塑产品组合，如计划将 CDMO 和细胞解决方案业务剥离给 GI Partners 所示。这些举措表明管理团队专注于简化、利润纪律和专注于差异化科学。([ir.criver.com](https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-announces-fourth-quarter-and-full-14/?utm_source=openai))
